Arthritis, Rheumatoid Clinical Trial
Official title:
Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China
Verified date | November 2023 |
Source | Qilu Hospital of Shandong University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to observed prospectively the efficacy and safety of 6 months and long-term treatment of Tacrolimus alone or with methotrexate (MTX) in moderate and severe Chinese RA patients who shown insufficiency response or intolerance to DMARDs
Status | Completed |
Enrollment | 150 |
Est. completion date | December 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis; 2. Age =18 years; 3. Patients have a history of DMARDs including csDMARDs(methotrexate,leflunomide, hydroxychloroquine, iguratimod, sulfasalazine) or any biologic DMARDs(TNFi,tocilizumab or Tofacitinib),prednisone or Chinese traditional Medicine(tripterygium Glycosides,Sinomenine)for 3 months, but couldn't achieve clinical remission, or couldn't tolerate one or more DMARDs; 4. Medium or high disease activity (DAS28=3.2); 5. Extra-articular manifestations (such as pulmonary fibrosis, proteinuria, leukopenia and peripheral neuropathy ) of RA patients are stable or no significant progress; 6. Dose of prednisone and NSAIDs remain stable for at least one month. Exclusion Criteria: 1. Patients with acute or chronic infections such as active bacterial, viral, fungal, tuberculosis infection or active hepatitis B; 2. Platelet counts(PLT) <80 x 10^9 / L, or white blood cell (WBC) <3 x 10^9 / L; 3. Propionate acid aminotransferase (ALT) or aspartate aminotransferase (AST) is two times higher than the upper limit of normal; 4. Renal insufficiency: serum Cr = 176 umol / L; 5. Pregnant or nursing women (breastfeeding) ; 6. Patients has a history of malignancy (cure time in less than 5 years); 7. Patients with severe or poorly controlled hypertension, diabetes or cardiac dysfunction; 8. Other comorbidities that cannot be treated with immune suppressants. In addition, once patients experience severe adverse drug reactions?ineffective treatment or rapid progression of rheumatoid arthritis, then quit this research. |
Country | Name | City | State |
---|---|---|---|
China | Qilu Hospital | Jinan | Shandong |
Lead Sponsor | Collaborator |
---|---|
Qiang Shu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Disease Activity Score 28 (DAS28-ESR) at 24 and longer weeks. | Change from baseline Disease Activity Score 28 (DAS28) erythrocyte sedimentation rate (ESR) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline ACR20 response rate at 24 and longer weeks. | Change from baseline ACR20 response rate at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | The clinical remission rate at 24 and longer weeks. | The percentage of patients who achieve clinical remission patients at the endpoint or withdraw timepoint. High disease activity: DAS28 score exceeding 5.1, Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1, Low disease activity (LDA): DAS28 score of less than or equal to 3.2, Remission: DAS28 score is less than 2.6. clinical remission means Low disease activity or remission. |
12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Clinical response was analyzed using the European League Against Rheumatism (EULAR) improvement criteria. | Good response: ?DAS28 > 1.2 and DAS28 =3.2; Moderate response: 1.2 =?DAS28 > 0.6 and 3.212 week,3 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| |
Secondary | Change from baseline Simplified Disease Activity Index (SDAI) at 24 and longer weeks. | Change from baseline Simplified Disease Activity Index (SDAI) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline Clinical disease activity index (CDAI) at 24 and longer weeks. | Change from baseline Clinical disease activity index (CDAI) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 and longer weeks. | Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline C-Reactive Protein (CRP) at 24 and longer weeks. | Change from baseline C-Reactive Protein (CRP) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline swollen joint number (SW28) at 24 and longer weeks. | Change from baseline swollen joint number (SW28) at 24 and longer weeks. SW28 means the number of joints with swelling counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline tenderness joint number (T28) at 24 and longer weeks. | Change from baseline tenderness joint number (T28) at 24 and longer weeks. T28 means the number of joints with tenderness upon touching counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline patient global assessment(PGA) at 24 and longer weeks. | Change from baseline patient global assessment(PGA) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline physician global assessment(PHGA) at 24 and longer weeks. | Change from baseline physician global assessment(PHGA) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Change from baseline Health Assessment Questionnaire (HAQ) at 24 and longer weeks. | Change from baseline Health Assessment Questionnaire (HAQ) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week | |
Secondary | Safety assessed by Adverse Events (AEs) | An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product | Up to 144 weeks | |
Secondary | Safety assessed by incidence of serious adverse events (SAE) | Adverse Event is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event. | Up to 144 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |